GSDME and systemic lupus erythematosus: After intraperitoneal injection of pristane, GSDME−/− mice exhibited ameliorated SLE pathogenesis, with reduced levels of autoantibodies, decreased proteinuria, and improved renal pathology (Fig. 3).